TY - JOUR
T1 - Assessing patient-reported peripheral neuropathy
T2 - The reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire
AU - Smith, Ellen M.Lavoie
AU - Barton, Debra L.
AU - Qin, Rui
AU - Steen, Preston D.
AU - Aaronson, Neil K.
AU - Loprinzi, Charles L.
N1 - Funding Information:
Acknowledgments This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported in part by Public Health Service grants CA-25224, CA-37404, CA-124477. CA-63848, CA-52352, CA-35090, CA-35101, CA-35269, CA-37417, CA-35448, CA-63844, CA-35267, CA-35272, CA-35113, CA-35103, CA-35415, and CA-35431. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institute of Health. A special thanks is extended to Suneetha Puttabasavaiah, BS for her assistance in data management.
PY - 2013/12
Y1 - 2013/12
N2 - Purpose This clinimetric analysis was conducted to evaluate the reliability, validity, and responsiveness to changeover time of the QLQ-CIPN20 when used to quantify patient-reported chemotherapy-induced peripheral neuropathy (CIPN). Methods Participants recruited to four cooperative group trials were pooled to create two groups (n = 376, 575): those who did versus did not receive neurotoxic chemotherapy. QLQ-CIPN20 internal consistency reliability was assessed using Cronbach's alpha coefficients. Instrument validity was assessed using factor analysis, by evaluating score correlations with other CIPN and pain measures, and by comparing scores between contrasting groups. Cohen's d was used to assess responsiveness to change. Results Alpha coefficients for the sensory, motor, and autonomic scales were 0.88, 0.88, and 0.78, respectively. However, autonomic scale and hearing loss items exhibited low item-item correlations (r B 0.30) and thus were deleted. Moderate correlations were found between QLQCIPN20 and Brief Pain Inventory pain severity items (r 0.30-0.57, p B .0001). Correlation between the QLQCIPN20 sensory and toxicity grading scale scores was low (r = .20; p B .01). Mean scores were higher (worse) (p B 0.0001) in individuals who did versus did not receive neurotoxic chemotherapy. The sensory and motor scales exhibited moderate-high responsiveness to change (Cohen's d = 0.82 and 0.48, respectively). Factor analysis indicated that the 16-item version formed distinct factors for lower and upper extremity CIPN, delineating typical distal to proximal CIPN progression. Conclusions Results provide support for QLQ-CIPN20 sensory and motor scale reliability and validity. The more parsimonious and clinically relevant 16-item version merits further consideration.
AB - Purpose This clinimetric analysis was conducted to evaluate the reliability, validity, and responsiveness to changeover time of the QLQ-CIPN20 when used to quantify patient-reported chemotherapy-induced peripheral neuropathy (CIPN). Methods Participants recruited to four cooperative group trials were pooled to create two groups (n = 376, 575): those who did versus did not receive neurotoxic chemotherapy. QLQ-CIPN20 internal consistency reliability was assessed using Cronbach's alpha coefficients. Instrument validity was assessed using factor analysis, by evaluating score correlations with other CIPN and pain measures, and by comparing scores between contrasting groups. Cohen's d was used to assess responsiveness to change. Results Alpha coefficients for the sensory, motor, and autonomic scales were 0.88, 0.88, and 0.78, respectively. However, autonomic scale and hearing loss items exhibited low item-item correlations (r B 0.30) and thus were deleted. Moderate correlations were found between QLQCIPN20 and Brief Pain Inventory pain severity items (r 0.30-0.57, p B .0001). Correlation between the QLQCIPN20 sensory and toxicity grading scale scores was low (r = .20; p B .01). Mean scores were higher (worse) (p B 0.0001) in individuals who did versus did not receive neurotoxic chemotherapy. The sensory and motor scales exhibited moderate-high responsiveness to change (Cohen's d = 0.82 and 0.48, respectively). Factor analysis indicated that the 16-item version formed distinct factors for lower and upper extremity CIPN, delineating typical distal to proximal CIPN progression. Conclusions Results provide support for QLQ-CIPN20 sensory and motor scale reliability and validity. The more parsimonious and clinically relevant 16-item version merits further consideration.
KW - Chemotherapy
KW - EORTC QLQ-CIPN20
KW - Peripheral neuropathy
KW - Reliability
KW - Validity
UR - http://www.scopus.com/inward/record.url?scp=84892782989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84892782989&partnerID=8YFLogxK
U2 - 10.1007/s11136-013-0379-8
DO - 10.1007/s11136-013-0379-8
M3 - Article
C2 - 23543373
AN - SCOPUS:84892782989
SN - 0962-9343
VL - 22
SP - 2787
EP - 2799
JO - Quality of Life Research
JF - Quality of Life Research
IS - 10
ER -